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Abstract
Background
Pulmonary arterial hypertension (PAH) is a progressive chronic disease with poor out-
comes. One reason for poor prognosis is the lack of understanding regarding individual vari-
ability in response to treatment. Idiopathic PAH (IPAH) patients with bone morphogenetic
protein receptor type 2 (BMPR2) mutations have distinct phenotypes that are crucial for indi-
vidualized therapy but evidence regarding their prevalence and clinical features in the
Korean population is lacking. Therefore, the present study aimed to screen Korean IPAH
patients for BMPR2 mutations and analyze their clinical phenotypes.
Methods
We enrolled 73 unrelated IPAH patients for BMPR2 mutation screening between March
2010 to November 2015 from 11 hospitals in Korea. Thirty-three lineal family members from
6 families of BMPR2 mutation carriers were also screened.
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Results
Among 73 patients, 16 (22%) had BMPR2 mutations. Mutation carriers were younger (27
vs. 47 years; p = 0.02) and had a higher mean pulmonary arterial pressure (mPAP) than
non-carriers (64 vs. 51 mmHg; p<0.05). Of the 16 individuals with mutations, 5 deletion, 2
splice-site, 6 nonsense, and 3 missense mutations were found, among which, 9 were newly
identified mutation types. Patients less than 30 years old had more BMPR2 mutations (44
vs. 14%; p = 0.04) and a higher mPAP (64 vs. 50 mmHg; p = 0.04) compared with those
equaled to or over 30 years old. There were no differences in hemodynamic profiles or the
proportion of BMPR2 mutation carriers between groups according to sex.
Conclusion
The prevalence of BMPR2 mutations in Korean IPAH patients was 22%. Mutation carriers




Pulmonary arterial hypertension (PAH) is a rare and fatal disease characterized by pulmonary
vascular cell proliferation and a sustained increase in mean pulmonary artery pressure
(mPAP), leading to right heart failure and eventually death [1, 2]. Among the World Health
Organization (WHO) types of pulmonary hypertension (PH), idiopathic PAH (IPAH) is in
group 1 and includes sporadic and familial cases with or without known germline mutations
[3, 4]. An altered transforming growth factor-beta (TGF-β) related receptor signaling via the
bone morphogenetic protein receptor type 2 (BMPR2) is the most common germline muta-
tion [3]. Bone morphogenetic proteins are part of a TGF-β superfamily cytokine group regulat-
ing growth and differentiation of bone and cartilage that affect various cell types [5]. BMPR2 is
a type II receptor with a long carboxyl-terminal sequence following the intracellular kinase
domain [6]. Mutations in the BMPR2 gene result in loss of function and reduced downstream
signaling [7]. Such mutations are prevalent in cases of IPAH, where 55% to 75% of individuals
with familial history and up to 40% of individuals with idiopathic cases were found to be
BMPR2 mutation carriers [4, 8, 9].
Targeted therapy with the use of endothelin receptor antagonists, phosphodiesterase-5
inhibitors, and prostanoids have markedly improved the likelihood of survival [10]. Despite
such advances, poor prognosis is a reality for most individuals, in part due to the lack of under-
standings regarding individual phenotypic variability [11, 12]. One of the most well-described
and most prevalent examples of individual variability in IPAH is the BMPR2 mutation [13–
15]. Heterozygous BMPR2 mutation carriers usually present 10 years earlier than non-carriers
[14] and are associated with more severe hemodynamic deterioration at diagnosis [14–16],
respond poorly to vasodilators [16, 17], and are at higher risk of lung transplantation, although
evidence regarding survival is debatable [7, 18, 19]. Understanding the phenotypic variabilities
of BMPR2 mutations may be crucial for individualized treatment strategies to improve
outcomes.
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Although there have been several case reports regarding BMPR2 mutations in Korean
IPAH patients [20], there is no established nationwide Korean multi-center cohort to study
BMPR2 mutations to date. Therefore, this study aimed to screen Korean IPAH patients for
BMPR2 mutations and investigate the mutation prevalence, clinical characteristics, and hemo-
dynamic profile of carriers.
Materials and methods
Subjects
The Effect of BMPR2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in
Pulmonary Arterial Hypertension (PILGRIM) cohort is a prospective, investigator-initiated,
multi-institutional clinical trial (NCT01054105). The study protocol was reviewed and
approved by the institutional review board of each participating center (GIRBA-2278; Gachon
University Gil Medical Center, Seoul National University Hospital, Severance Cardiovascular
Hospital at Yonsei University College of Medicine, Samsung Medical Center, Seoul National
University Bundang Hospital, Wonkwang University Hospital, Seoul St. Mary’s Hospital of
The Catholic University, Sejong General Hospital, Soonchunhyang University Hospital, Chon-
nam National University Hospital, and Hanyang University Medical Center).
The PILGRIM study was designed with two phases. The first phase was to evaluate the prev-
alence, hemodynamic features, and short-term outcomes of Korean individuals with IPAH.
The second phase of the study will focus on the hemodynamic response to iloprost inhalation.
Herein, we present the first phase of the PILGRIM study.
All patients gave informed consents for participation. Clinical data were acquired from
electronic medical records. Telephone interviews were conducted for patients lost during fol-
low-up. Consecutive patients diagnosed with IPAH at 11 participating hospitals were enrolled
and followed between March 1, 2010, and November 30, 2015. The inclusion criteria were: (1)
patients aged between 20 to 80 years; (2) those with WHO group I PH (mPAP>25 mmHg
and pulmonary artery wedge pressure [PAWP]<15 mmHg) confirmed by right heart cathe-
terization (RHC) or those who satisfied the echocardiographic criteria (peak pulmonary arte-
rial pressure>40mmHg and mPAP>30mmHg); (3) previously diagnosed PAH patients
refractory to conventional treatment excluding iloprost inhalation solution (Ventavis™), and;
(4) able to undergo a low-intensity exercise test (bicycle or walking). Exclusion criteria were
patients with PH belonging to WHO groups II-V and patients concurrently using other pul-
monary artery vasodilators such as an inhaled nitric oxide (NO) or endothelin antagonists
except for phosphodiesterase-5 inhibitors. Detailed inclusion and exclusion criteria are shown
in S1 Table. Other test modalities such as pulmonary function testing, chest computed tomog-
raphy, perfusion scan, human immunodeficiency virus blood tests, and connective tissue dis-
ease markers were used to rule out other specific causes among those without WHO group I
PH.
The definition of IPAH in the current study
In this study, IPAH was defined as individuals with WHO group I PH without apparent cause
regardless of family history, which included all cases of sporadic or familial PAH. The sporadic
and familial cases were not separately analyzed because they have indistinguishable histopath-
ological and clinical phenotypes [21]. Additionally, BMPR2-associated PAH is an autosomal
dominant disease with variable penetrance, indicating that all BMPR2 mutation carriers have
the heritable disease regardless of the clinical presentation of family members [13]. Thus, a
total of 33 lineal family members of all BMPR2 mutation-positive patients (33 lineal family
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members among 16 families of 16 mutation carriers) were examined. A diagram for enroll-
ment is shown in Fig 1.
Hemodynamic measurements
All diagnoses were confirmed by RHC. RHC was performed to measure hemodynamic values
at initial diagnosis for all patients. The mPAP, PAWP, cardiac output, and pulmonary vascular
resistance (PVR) were recorded.
Molecular methods
Blood samples of patients were collected in vacuum blood collection tubes containing ethyl-
enediaminetetraacetic acid. Genomic DNA was extracted from the blood or buffy coat samples
using an Exgene Blood SV mini-kit (GeneAll, Korea) according to the manufacturer’s proto-
col. All exons and the flanking intronic sequences of the BMPR2 gene were amplified by poly-
merase chain reaction using PrimeSTAR HS DNA Polymerase (TAKARA, Japan) and the
appropriate primer sets. The primers used in this study are shown in S2 Table. Polymerase
chain reaction products were purified using an Expin Combo GP kit (GeneAll, Korea). The
purified samples were subsequently subjected to direct sequencing using a BigDye Terminator
Fig 1. Diagram for detailed enrollment. The study population included 73 individuals with IPAH who were
evaluated for BMPR2 mutations. Sixteen individuals were positive for BMPR2 mutation, among which 7 had at least
one BMPR2 mutation-positive family member. Fifty-seven individuals were BMPR2 mutation carriers, whereas 17
were non-carriers. Abbreviations: PAH, pulmonary arterial hypertension; BMPR2, bone morphogenetic protein
receptor type 2; IPAH, idiopathic pulmonary arterial hypertension.
https://doi.org/10.1371/journal.pone.0238698.g001
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v3.1 cycle sequencing kit (Life Technologies, USA) and ABI 3730xl DNA Analyzer (Applied
Biosystems, USA). The GenBank accession numbers for the reference sequences used in this
study were NM_001204.6 for cDNA and NC_000002.12 for the genomic DNA of BMPR2.
Literature search
We obtained cohort or meta-analysis data regarding individuals with IPAH with or without
BMPR2 mutations through a systematic search of the Cochrane Library, PubMed/MEDLINE,
and Web of Science databases. The search terms were: 1) “BMPR2” OR “bone morphogenetic
protein receptor type 2”; AND 2) “idiopathic PAH,” OR “heritable PAH” OR “sporadic PAH,”
OR “familial PAH.” As a result, 11 studies contained relevant data with more than 50 patients
enrolled.
Statistical analysis
Data are presented as mean±standard deviation for normally distributed data, whereas contin-
uous non-normally distributed data are given as a median and interquartile range (IQR). Dis-
crete data are given as numbers and/or percentages. P-values less than 0.05 were considered
statistically significant. The clinical and hemodynamic parameters between BMPR2 mutation
carriers and non-carriers were compared The Pearson χ2 test and Mann-Whitney U-test were
used to compare normally and non-normally distributed data, respectively. The median fol-
low-up was analyzed among those who did not die during follow-up. Mortality rates between
groups were not analyzed due to a lack of statistical power. Statistical analyses were performed
using SPSS v. 23.0 for Windows (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics
We enrolled a total of 73 Korean patients diagnosed with IPAH from 11 health centers in
Korea. Table 1 summarizes the demographic variables, functional/hemodynamic status, and
drug regimen in BMPR2 mutation carriers and non-carriers. The mean age at initial diagnosis
regardless of etiology was 42.7±19.8 years and 27% were men. The mean age at diagnosis for
carriers was lower than non-carriers by approximately 20 years (27.2±11.1 vs. 46.6±19.6 years;
p = 0.022). The mutation carriers showed a higher mPAP than the non-carriers (63.7±17.3 vs.
50.5±15.2 mmHg; p< 0.05). Additionally, the PAWP in the carriers was significantly lower
than in the non-carriers (6.8±2.2 vs. 10.8±3.5 mmHg; p = 0.020). Other hemodynamic profiles
including PVR and cardiac output showed no significant differences between the two groups.
The proportion of patients on PAH targeted therapy, including prostaglandin I2 (PGI2), phos-
phodiesterase-5 inhibitors, endothelin receptor antagonists, and tyrosine kinase inhibitors
were similar between the two groups (Table 1). The median follow-up duration of the cohort
was 1.5 years (IQR, 1.0 to 2.2) (Table 1). The median follow-up of the carrier and non-carrier
groups was 1.0 and 1.3 years, respectively (p = 0.806). Zero carriers but 4 non-carriers died
during follow-up (Table 1).
A total of 33 lineal family members of the 16 IPAH BMPR2 mutation-positive patients
agreed to undergo screening examinations (Fig 1). One to five members in addition to the pro-
band of each family were evaluated. Seven families had at least 1-member tested positive for
the BMPR2 mutation (S3 Table). Penetrance of the BMPR2 mutation was not evaluated due to
the lack of information regarding the clinical symptoms of each family member.
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BMPR2 mutations
We found BMPR2 mutations in 21.9% (16/73) of Korean individuals with IPAH (Table 2).
Among the 16 mutations, 6 (37.5%) were nonsense, 5 (31.3%) were deletion, 2 (12.5%) were
splice-site, and 3 (18.8%) were missense types. Six (37.5%) mutation types were previously
reported [7, 22–24] and 2 nonsense mutations were identified in 2 different individuals. Of the
9 novel mutation types identified in the current study, 5 were deletion, 2 were splice site, one
was nonsense, and one was missense (Table 2).
Subgroup analysis
Further stratified analysis was performed according to age and sex (Table 3). In patients under
the age of 30, the proportion of BMPR2 mutation carriers were significantly higher than the
non-carriers (43.8% vs. 15.7%; p<0.001). The mean age difference between the younger and
older groups was approximately 30 years. All deaths occurred in the older group (Table 3).
There were no significant differences in age, hemodynamic profiles, or death between the
sexes (Table 3).
Discussion
According to the present study, the prevalence of BMPR2 mutations in Korean individuals
with IPAH is 21.9%. In addition, Korean BMPR2 mutation carriers are younger and have
Table 1. Demographic and clinical characteristics of BMPR2 carriers and non-carriers.
BMPR2 mutation




Men, n (%) 19 (26) 4 (25) 15 (26) 0.857
Age (y), mean±SD 42.2±19.7 27.2±11.1 46.6±19.6 0.022�
Functional and hemodynamic status
NYHA functional class�II, n (%) 52 (71) 10 (63) 42 (74) 0.270
mPAP, mmHg 53.3±16.5 63.7±17.3 50.5±15.2 <0.001�
PAWP mmHg 15.8±12.3 6.8±2.2 10.8±3.5 0.020�
PVR, mmHg/L/min 10.2±8.9 11.5±9.6 9.9 ±8.8 0.722
Cardiac output, L/min 4.2±2.2 3.7±1.2 4.3±2.4 0.092
PAH targeted therapy
Prostaglandin I2, n (%) 20 (27) 2 (13) 18 (32) 0.391
PDE5i, n (%) 14 (19) 3 (19) 11 (19) 0.854
ERA, n (%) 38 (52) 10 (63) 28 (49) 0.649
TKI, n (%) 2 (3) 0 (0) 2 (4) 0.587
Follow-up data
Median follow-up years (IQR)† 1.5 (1.0–2.2) 1.0 (1.0–2.1) 1.3 (0.9–2.3) N/A
Death, n (%) 4 (5) 0 (0) 4 (7) N/A
Abbreviations: BMPR2, bone morphogenetic protein receptor type 2; SD, standard deviation; NYHA, New York Heart Association; mPAP, mean pulmonary arterial
pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; PDE5i, phosphodiesterase-5 inhibitors; ERA, Endothelin receptor antagonists;
TKI, tyrosine kinase inhibitors. IQR, interquartile range
�P < 0.05
#Mann-Whitney test
† Median follow-up information was gathered among survivors only
https://doi.org/10.1371/journal.pone.0238698.t001
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poorer hemodynamic profiles at diagnosis than non-carriers. Survival analysis was not per-
formed in the current study due to the lack of statistical power.
The discovery of the association between PAH and BMPR2 mutations has led to a better
understanding of the pathobiology of PAH. BMPR2 mutations increase the susceptibility to
apoptosis in the endothelial cells and promote the proliferation of pulmonary arterial vascular
smooth muscle cells [25]. These changes in the vasculature are thought to accelerate the
Table 3. Demographic characteristics, BMPR2 mutation status, hemodynamic profile, and clinical outcomes of
subgroups.
Age at diagnosis
< 30 (n = 16) � 30 (n = 57) P-value
Age (y), mean±SD 20±7 50±17 <0.001
BMPR2 mutation carriers, n (%) 7 (43.8) 8 (14.0) 0.035
mPAP, mmHg 64±15 50±16 0.003
PAWP mmHg 20±12 15±13 0.314
PVR, mmHg/L/min 12±8 10±9 0.433
Cardiac output, L/min 3.9±1.1 4.3±2.4 0.652
Sex
Male (n = 19) Female (n = 54) P-value
Age (y), mean±SD 49±21 41±19 0.13
BMPR2 mutation carriers, n (%) 4 (21.0) 11 (20.0) 9.86
mPAP, mmHg 50±14 54±17 0.363
PAWP mmHg 15±10 16±13 0.882
PVR, mmHg/L/min 7.8±4.8 11.1±9.8 0.258
Cardiac output, L/min 5.1±2.4 3.9±2.1 0.093
Abbreviations: SD, standard deviation; BMPR2, bone morphogenetic protein receptor type 2; mPAP, mean
pulmonary arterial pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance
https://doi.org/10.1371/journal.pone.0238698.t003
Table 2. Description of BMPR2 mutation-positive genes.
Patient Classification Location Mutation type Nucleotide change Protein change Reference Number
1 idiopathic exon 6 nonsense c.631C>T p.Arg211X [10]
2 idiopathic exon 8 nonsense c.994C>T p.Arg332X [10]
3 idiopathic exon 12 nonsense c.2695C>T p.Arg899X [4]
4 idiopathic 5’UTR-exon1 deletion c.1-1_8del p.? novel
5 idiopathic exon 9 missense c.1258T>C p.Cys420Arg [26]
6 heritable exon 4 deletion c.451del p.Ile151fs novel
7 idiopathic exon 8 deletion c.1042-1047del p.Val348_Ile349del novel
8 heritable intron 5 splice site c621+1G>T p.? novel
9 heritable exon 8 deletion c.1028del p.Asn343fs novel
10 heritable intron6 splice site c.853-2A>C p.? novel
11 heritable exon12 nonsense c.2695C>T p.Arg899X [4]
12 heritable exon11 deletion c.1448delGT p.Cys483fs novel
13 idiopathic exon 6 nonsense c.846T>G p.Tyr282X novel
14 idiopathic exon 9 missense c.1226T>C p.Leu409Pro novel
15 heritable exon11 missense c.1471C>T p.Arg491Trp [28]
16 idiopathic exon 8 nonsense c.994C>T p.Arg332X [10]
Abbreviation: UTR, untranslated region
https://doi.org/10.1371/journal.pone.0238698.t002
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development of PAH [26]. Previous studies report that BMPR2 mutation carriers present at
initial diagnosis at an earlier age and have more severe hemodynamic profile than non-carriers
[14–16, 27]. The age of PAH diagnosis for the BMPR2 gene mutation carriers has been
reported to be 10 years earlier than in non-carriers, with the mean age ranging between 28 and
38.5 years [7, 13, 14, 16, 17, 19, 22–24, 28]. However, the present study data show that the
BMPR2 mutation carriers were diagnosed at the age of 27.9±11.4 years, which is approximately
10 years younger than the age of diagnosis in all international cohorts except for the Chinese
[7, 13, 15–17, 19, 22, 24, 28, 29]. Thus, Korean BMPR2 mutation carriers were 20 years youn-
ger than their non-carrier counterparts.
Despite the age gap between the two groups, BMPR2 mutation carriers in the present study
showed the highest gap of mPAP (13.2 mmHg) between carriers and non-carriers compared
with other cohorts, including meta-analysis data, which only showed a 2 to 7 mmHg gap
(Table 4) [7, 13, 15–17, 19, 22, 24, 28, 29]. Although the present study showed similar trends of
higher mPAP at diagnosis in BMPR2 mutation carriers compared to non-carriers, the uniquely
high mPAP warrants further investigation. These results also indicate the importance of early
screening for BMPR2 for the initiation of aggressive treatment in patients to ensure better out-
comes [10]. This has been previously suggested for the Japanese population which possesses
similar genetic background [30].
The prevalence of BMPR2 mutations and the differences between characteristics of BMPR2
carriers and non-carriers in the present study were similar to most cohorts in the literature,
representing the United States (US), France, Germany, China, and Japan [7, 14–17, 19, 22, 24,
28], except for a single cohort from the US which mainly recruited familial cases (125 out of
169, 74%), as shown in Table 4 and Fig 2 [13]. All other cohorts enrolled familial cases to a sim-
ilar degree (6 to 22%). The overall prevalence of BMPR2 mutations in Korean IPAH patients
was 22%, which is slightly higher than observed in Chinese and lower than in Japanese cohorts
(Fig 2) [19, 22, 24, 28]. Data from Asian populations are limited, and the prevalence of BMPR2
mutation differs between Japanese (36–41%) and Chinese (16–29%) studies (Fig 2) [19, 25, 27,
29]. This may be partly explained by the Chinese cohort having a relatively low percentage of
familial cases (6%) compared with the Japanese (18%) [19, 24], considering that familial cases
of PAH have a much higher prevalence of mutation carriers (70%) than sporadic cases (20%)
[31]. It may also be suggested that the higher prevalence of BMPR2 mutation carriers in Japa-
nese cohorts may be due to the underestimation of familial cases because Asian patients are
generally reluctant to share information about inherited diseases because they are considered a
source of shame.
The percentage of patients carrying BMPR2 mutations was significantly higher in patients
younger than 30, compared with patients aged 30 or higher. This was consistent with the
meta-analysis data, suggesting that BMPR2 mutation may play a crucial role in the early devel-
opment of PAH and severe hemodynamic symptoms [7]. Our study also shows that PAH
patients were predominantly women (male:female, 1:2.8), although there was no difference in
the proportion of BMPR2 mutation carriers, hemodynamic profiles, or death according to sex
[32].
The influence of BMPR2 mutations on clinical outcomes has been a topic of controversy.
Earlier studies reported that BMPR2 mutation status does not affect overall survival or risk for
lung transplantation [33]. A Japanese study found that the overall survival of BMPR2 mutation
carriers may be better than non-carriers due to ethnicity or the introduction of PGI2 infusion
therapy [28]. On the other hand, a study with a Chinese cohort demonstrated that BMPR2
mutation carriers had a significantly poorer survival, although the use of PGI2 or other medi-
cation was not specified [22]. According to a recent meta-analysis, mutation carriers had
poorer outcomes especially in younger patients; however, information regarding
PLOS ONE BMPR2 mutation in Korean IPAH patients
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comorbidities or PAH-targeted medication was not investigated [7]. Although we did not
include a survival analysis in the present study due to the lack of statistical power, the BMPR2
mutation carrier group had a higher percentage of deaths compared with the non-carrier
group. It is most likely that this is by chance considering the small sample size and short fol-
low-up. However, the trend is consistent with Japanese studies [10] that share a common east
Asian heritage [34]. Also, the BMPR2 mutation carriers in the current study were approxi-
mately 8 years younger than those in the meta-analysis [7].
Table 4. Comparison of clinical and hemodynamic features of BMPR2 mutation carriers and non-carriers.













Korea IPAH Present (N = 16) 1/3.0 27.2
±11.1
63.7±17.3 10.1±2.4 2.1±0.4 - -
Absent (N = 57) 1/2.8 46.6
±19.6
50.5±15.2 8.3±1.1 2.3±0.4
Japan IPAH and HPAH Present (N = 26) 1/4.8 35±13 57.7±14.5 19.1±7.3� 1.9±0.5 - Isobe [28]
Absent (N = 36) 1/1.8 34±11 55.7±15.1 16.9±9.0� 2.2±1.0
Japan IPAH and HPAH Present (N = 18) 1/2.2 37.4
±12.7
60.8±15.4 21.5±9.4 - 18 Kabata [19]
Absent (N = 31) 1/1.7 25.9
±11.3
58.8±12.0 18.6±8.6 -
China IPAH and HPAH Present (N = 50) 1/1.3 28±2 67±6 17.1±2� 2.0±0.2 - Liu [22]
Absent
(N = 255)
1/2.9 32±4 60±6 14.6±2� 2.3±0.2






US IPAH and HPAH Present (N = 41) 1/2.2 36.1±1.4 58.6±1.7 18.1±2.0� 1.9±0.1 74 Austin [13]
Absent
(N = 106)
1/3.1 42±2.3 58.3±1.7 14.0±0.8� 1.8±0.2
US IPAH and HPAH Present (N = 27) 1/1.0 37.1
±12.0
60.7±10.5 14.6±5.1 2.1±0.6 18 Elliott [17]
Absent (N = 40) 1/6.0 38.2
±10.9
56.9±11.3 12.3±6.1 2.3±0.7
US IPAH and HPAH Present (N = 23) - - 61±13 26±14 2.0±1.1 22 Rosenzweig
[16]Absent
(N = 124)
- - 59±20 21±14 2.4±1.5
France IPAH and HPAH Present (N = 68) 1/2.0 36.5
±14.5






Germany IPAH and HPAH Present (N = 49) 1/1.9 38.5
±11.8












1/3.2 35±15 60.5±13.8 16.6±8.3� 2.1±0.7 15 Evans [7]
Absent
(N = 1102)
1/3.6 42±18 56.4±15.3 12.9±8.3� 2.5±0.9
Abbreviations: BMPR2, bone morphogenetic protein receptor type 2; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary artery wedge pressure; PVRI,
pulmonary vascular resistance index; CI, confidence interval; IPAH, idiopathic pulmonary arterial hypertension; HPAH, heritable pulmonary arterial hypertension
�Pulmonary vascular resistance is presented due to the lack of data regarding pulmonary vascular resistance index (units: mmHg/L/min)
https://doi.org/10.1371/journal.pone.0238698.t004
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The main limitation of this study was the small sample size and lack of information regard-
ing family history. All 11 centers experienced difficulties enrolling patients, as the majority of
the patients and family members were reluctant to share their genetic information and symp-
toms, which can be used against them in Korean society. In Asian societies, sharing information
regarding heritable diseases is taboo because it is generally perceived as a shame. Therefore, we
were not able to gather hemodynamic profiles or data on symptoms from all family members,
hampering the effort to include individuals with heritable PAH. The Genetic Information Non-
discrimination Act (GINA) is a law that protects individuals from being discriminated against
by insurance companies or employers after participating in research or genetic testing [35]. As
Korean society has no protective measures against genetic discrimination, such as the GINA in
the US, fear of being discriminated against dissuaded many patients from participating in this
study. Legislative initiatives for genetic nondiscrimination are necessary for the continuation of
genetic research in Korea. Another limitation of the study was that the phenotypic expression of
each genetic mutation was not investigated. Future studies involving multi-omics data and deep
phenotyping in Korean individuals with PAH are warranted [11].
Conclusions
In the PILGRIM study, the BMPR2 mutation carriers were 20 years younger and had higher
mPAP than the non-carriers. Despite these discrepancies in baseline characteristics upon
Fig 2. The worldwide prevalence between BMPR2 mutation carriers and non-carriers in patients with idiopathic or heritable pulmonary arterial
hypertension. The overall prevalence of BMPR2 mutation carriers in IPAH patients in Korea was 22%, which is higher than in China and lower than in
Japan. BMPR2 = bone morphogenetic protein receptor type 2.
https://doi.org/10.1371/journal.pone.0238698.g002
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initial diagnosis, there was no statistical difference in all-cause mortality among the two
groups.
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